AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06012851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In the moment feedback
Description: In-the-moment feedback will include parenting feedback.
Study NCT06012851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In the moment suggestions
Description: In-the-moment feedback will include suggestions for parenting strategies.
Study NCT05023460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paresthesia-free (burst) ONS
Description: Stimulation intensity target of 60% of paresthesia threshold.
Study NCT05023460 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ONS system deactivated
Study NCT05373472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: 2 doses of vaccine on Day 0 and Day 21
Study NCT05373472 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo on Day 0 and Day 21
Study NCT06438458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postural change from supine to sitting
Description: Patients go from supine to sitting position in bed (passive)
Study NCT06438458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization to a chair
Description: Patients go from the bed to sitting in a chair (active)
Study NCT03886402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: Treatment of erectile dysfunction with the subjects own cells
Study NCT06004505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular Rehabilitation
Description: The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
Study NCT04753619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Oral Tablet
Description: * NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Study NCT06426173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training Program
Description: The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.
Study NCT06426173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment Group
Description: Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
Study NCT06426173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Group
Description: Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
Study NCT04436978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30-day DAPT
Description: DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
Study NCT04436978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed therapy
Description: Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
Study NCT04764006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
Study NCT04936828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
Study NCT04883970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 124I-18B10(10L) PET/CT
Description: Study participants will undergo 124I-18B10(10L) PET/CT scans
Study NCT05426304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: agomelatine 25 mg/day for 180 days
Study NCT05426304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: placebo 25 mg/day for 180 days
Study NCT05000970 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: blood pressure cuff PLUS tablet
Description: all arms
Study NCT05000970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood pressure cuff PLUS tablet
Description: all arms
Study NCT05000970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Consult
Description: Telehealth consult with an RN
Study NCT06301503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USG Guided Combined LPB-SNB with Isobaric Bupivacaine
Description: Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
Study NCT06301503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Local anesthetic infiltration of 2% lidocaine (3ml)
Study NCT06300424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almonertinib
Description: 110mg qd
Study NCT06300424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, d1 every 3 weeks
Study NCT06300424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 135 mg/m2, d1,d8 every 3 weeks
Study NCT06031012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine combined with thalidomide
Description: Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
Study NCT06031012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutamine alone
Description: Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
Study NCT01484353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coronary Health Improvement Project Program
Description: The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
Study NCT06518668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
Study NCT04717102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 MAC desflurane
Description: Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
Study NCT04717102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75 MAC desflurane
Description: Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
Study NCT04717102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 MAC desflurane
Description: On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
Study NCT04717102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Description: On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
Study NCT06091852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intrinsically labelled milk protein
Description: 20 grams of protein dissolved in 500 mL of water
Study NCT05855083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: narsoplimab
Description: Treatment with narsoplimab 4 mg/kg will be administered
Study NCT06518668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide LD
Description: Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)
Study NCT04542733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus will be given with tacrolimus.
Study NCT04542733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reduced dose tacrolimus
Description: Reduced dose tacrolimus will be given with or without leflunomide
Study NCT04775654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant
Description: Two capsules containing 455mg of CurrantCraft 11% black currant extract.
Study NCT04775654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules containing an inert material.
Study NCT05572060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
Study NCT05572060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized protocol
Description: standardized protocol
Study NCT04775992 — intervention group
Intervention type: OTHER
Intervention: gabapentoids
Description: Preemptive analgesia
Study NCT05791682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealant, Fissure
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
Study NCT04823962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF + hydrogel
Description: The active substance: molgramostim (rhGM-CSF)
Study NCT04823962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydrogel
Description: Placebo hydrogel
Study NCT04823962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Compression therapy and neutral dressings
Study NCT04823962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Compression therapy and neutral dressings
Study NCT05456711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
Description: ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
Study NCT05484453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Eye Examination by Ophthalmologist
Description: complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
Study NCT05544565 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV Antibacterial Agents
Description: Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
Study NCT05544565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Antibacterial Agents
Description: Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
Study NCT05544565 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orally antibacterial agents
Description: Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
Study NCT05544565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fecal/Rectal Swab
Description: Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
Study NCT05544565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal/Rectal Swab
Description: Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
Study NCT05544565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCT assay
Description: Dosage of procalcitonin (if not performed in standard care) at D0
Study NCT05544565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCT assay
Description: Dosage of procalcitonin (if not performed in standard care) at D0
Study NCT05544565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal scintigraphy
Description: A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars
Study NCT05544565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal scintigraphy
Description: A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars
Study NCT05461118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental:Treatment group
Description: Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
Study NCT05051501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics C2P
Description: Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
Study NCT04463498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral therapy for insomnia
Description: Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
Study NCT04463498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral therapy for insomnia and additive bb-glasses
Description: Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
Study NCT04463498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8-week wait list for sleep-school
Description: Treatment as usual in a psychiatric outpatient clinic
Study NCT05617742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46
Description: 68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
Study NCT06554743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Veg
Description: Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
Study NCT06554743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Default Meat
Description: Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
Study NCT06215092 — intervention group
Intervention type: OTHER
Intervention: Psychological assessment
Description: Psychological assessment of cognitive and social-emotional functioning.
Study NCT06246305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy training
Description: conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance, and scapular stabilization exercises. The intervention is done 3 times per week for 12 weeks.
Study NCT06246305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Description: During the on-brace phase (0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. this program involves warming up and down stretching exercises and exercise training that includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. The intervention is done 3 times per week for 12 weeks.
Study NCT05202912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IDX-1197(After a meal)
Description: randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
Study NCT05202912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IDX-1197(fasting)
Description: open-label, single-dose study in Chinese male volunteers
Study NCT06233500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy
Description: All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~* 23 G trocar system will be used~* Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~* Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~* Shaving of the vitreous base, and then fluid air exchange~* SF 6 gas tamponade will be used
Study NCT04548973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine
Study NCT04548973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2ml normal saline
Study NCT06061042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time restricted eating
Description: Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
Study NCT06061042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time restricted eating
Description: Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM